# US 2025/0084384 A1 · Chimeric poxvirus compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084384 A1
- Document ID: US20250084384A1
- Status: Published application
- Kind: A1
- Application number: 18/776,109
- Filed: 2024-07-17
- Published: 2025-03-13
- Earliest claimed: 2016-08-09
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Yuman Fong; Nanhai Chen
- Web page: https://patentgrep.com/patent/US20250084384A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/275: Poxviridae, e.g. avipoxvirus
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 15/86: Viral vectors
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2710/24121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/24132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2710/24151: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are, inter alia, viral compositions and methods of using the same. The viral compositions provided include, inter alia, therapeutically effective amounts of a chimeric poxvirus and are particularly useful for methods of treating cancer. The chimeric poxviruses provided herein may further include transgenes.

## Claims

### Claim 1

A chimeric poxvirus comprising a nucleic acid sequence having a sequence identity of at least 95%1 to positions 5,014 to 185,366 of SEQ ID NO:1 or to SEQ ID NO:2, wherein said nucleic acid sequence further comprises:
(i) one or more anti-cancer nucleic acid sequences inserted into said nucleic acid sequence; or
(ii) a detectable moiety-encoding nucleic acid sequence inserted into said nucleic acid sequence.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The chimeric poxvirus of claim 1, wherein said one or more anti-cancer nucleic acid sequences or said detectable moiety-encoding nucleic acid sequence is inserted into a non-essential gene of said chimeric poxvirus.

### Claim 4 (depends on 3)

The chimeric poxvirus of claim 3, wherein said non-essential gene is a thymidine kinase gene or a F14.5L gene.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The chimeric poxvirus of claim 1, wherein said one or more anti-cancer nucleic acid sequences independently encode a PD-L1 inhibitor or a sodium iodide symporter.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The chimeric poxvirus of claim 1, wherein said one or more anti-cancer nucleic acid sequences are each operably linked to a promoter.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The chimeric poxvirus of claim 9, wherein said promoter is a synthetic early promoter.

### Claim 12

(canceled)

### Claim 13 (depends on 9)

The chimeric poxvirus of claim 9, wherein said promoter is a H5 promoter or an 11K promoter.

### Claim at position 14

-18. (canceled)

### Claim 19 (depends on 1)

The chimeric poxvirus of claim 1, wherein said one or more anti-cancer nucleic acid sequences independently encode for a miRNA binding sequence.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The chimeric poxvirus of claim 1, wherein said one or more anti-cancer nucleic acid sequences are a first anti-cancer nucleic acid sequence and a second anti-cancer nucleic acid sequence.

### Claim at position 18

-24. (canceled)

### Claim 25 (depends on 21)

The chimeric poxvirus of claim 21, wherein said first anti-cancer nucleic acid sequence encodes a sodium iodide symporter and said second anti-cancer nucleic acid sequence encodes a PD-L1 inhibitor.

### Claim 26 (depends on 25)

The chimeric poxvirus of claim 25, wherein said first anti-cancer nucleic acid sequence forms part of a thymidine kinase gene and said second anti-cancer nucleic acid sequence forms part of a F14.5L gene.

### Claim at position 21

-40. (canceled)

### Claim 41 (depends on 1)

The chimeric poxvirus of claim 1, wherein said nucleic acid sequence has a sequence identity of at least 98% to positions 5,014 to 185,366 of SEO ID NO:1 or to SEO ID NO:2.

### Claim at position 23

-46. (canceled)

### Claim 47 (depends on 1)

The chimeric poxvirus of claim 1, wherein said chimeric poxvirus is an oncolytic virus.

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50 (depends on 1)

An isolated nucleic acid encoding a chimeric poxvirus of claim 1.

### Claim 51 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of claim 1.

### Claim 52 (depends on 1)

A method of treating cancer in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of said chimeric poxvirus of claim 1, thereby treating cancer in said subject.

### Claim 53 (depends on 52)

The method of claim 52, wherein said cancer is breast cancer, colon cancer, kidney cancer, leukemia, lung cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer, brain cancer, liver cancer, gastric cancer or a sarcoma.

### Claim 54

(canceled)

### Claim 55 (depends on 52)

The method of claim 52, wherein said administering comprises administering said chimeric poxvirus and a second chimeric poxvirus.

### Claim at position 33

-67. (canceled)

### Claim 68

A method of forming a chimeric poxvirus, said method comprising:
(i) infecting a cell with at least two poxvirus strains selected from the group consisting of cowpox virus strain Brighton, raccoonpox virus strain Herman, rabbitpox virus strain Utrecht, vaccinia virus strain WR, vaccinia virus strain IHD, vaccinia virus strain Elstree, vaccinia virus strain CL, vaccinia virus strain Lederle-Chorioallantoic, vaccinia virus strain AS, orf virus strain NZ2 and pseudocowpox virus strain TJS; and
(ii) allowing said at least two poxvirus strains to replicate, thereby forming said chimeric poxvirus.

### Claim at position 35

-75. (canceled)

### Claim 76 (depends on 1)

A method of inhibiting cell proliferation of a cell, said method comprising contacting a cell with a chimeric poxvirus of claim 1.

### Claim at position 37

-79. (canceled)
